Clinical Observation Of DC/CIK Cells And Gefitinib In Treatment Of EGFR Mutations In Advanced Non-small Cell Lung Cancer

[Objective] to study the combined therapy with DC/CIK cells and gefitinib of EGFR mutations in non-small cell lung cancer (NSCLC), the safety and Efficacy.[Methods] EGFR mutations in NSCLC patients, random number method combined and single drug group, the treatment group joint DC/CIK therapy, single drug group only the treatment of oral treatment, compared two groups of curative effect.[Results] (1) in the near future curative effect of combined set of DCR (efficient) recently, RR (disease control rates were 55.6%,82.2%, significantly higher than that of single drug group 40.0%,73.3%, the difference was statistically significant (P< 0.05).(2) Peripheral blood lymphocyte phenotypes:after treatment in the combined group of peripheral blood CD3+, CD4+, CD4+/CD8+, NK the index increased slightly, compared with before treatment, single drug group decreased significantly (P < 0.05), after treatment the index of the combined group was significantly higher than that of the single drug group (P< 0.05).(3) the joint group of patients with pure chemoth-erapy group physical decline and reduce significantly decreased appetite, the difference was statistically significant (P< 0.05).(4) joint and single drug group PFS were 10.6 months and 8.1 months, and the joint group of PFS extended the 2.5 months, the difference was statistically significant (P< 0.05);(5)Adverse reactions: Two groups of patients with skin rash and diarrhea incidence were compared, the difference was not statistically significant (P>0.05). A group of patients with 5 cases of fever in the infusion of CIK, the temperature of 38-38.5 DEG C, by physical or drug cooling temperature returned to normal after infusion, again without fever; 3 cases of chest tightness in the intravenous drip of CIK 20 minutes, slow drop speed, reduce the symptoms of 2 cases; 1 cases of intravenous dexamethasone 5mg after 15 minutes of treatment, remission.[Conclusions] DC/CIK cells and gefitinib in treatment of EGFR mutations in NSCLC, could improve the patients’recent efficiently and disease control, reduce the effect of chemotherapy drugs to patients immunity, improve resistance, extend the patients survival, improve patient quality of life, and good security.